N-(2-aminopropanoyl)leucine | 1638-60-4

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 亮氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(2-aminopropanoyl)leucine
• 英文别名: dl-alanyl-l-leucine；(2S)-2-(2-aminopropanoylamino)-4-methylpentanoic acid
• CAS: 1638-60-4
• 化学式: C₉H₁₈N₂O₃
• 分子量: 202.254
• InChiKey: RDIKFPRVLJLMER-MLWJPKLSSA-N

物化性质

• 沸点：
  409.7±30.0 °C(Predicted)
• 密度：
  1.108±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.8
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  92.4
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• PRO-DRUGS OF (E)-7-(3-(2-AMINO-1-FLUOROETHYLIDENE)PIPERIDIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-8-METHOXY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID
  申请人：MACIELAG Mark

  公开号：US20110172193A1

  公开（公告）日：2011-07-14

  The present invention is directed to pro-drugs of (E)-7-(3-(2-amino-1-fluoroethylidene)piperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, pharmaceutical compositions containing them and the use of said pro-drugs and pharmaceutical compositions as antimicrobial agents against pathogenic microorganisms, particularly against resistant microbes.

  本发明涉及(E)-7-(3-(2-氨基-1-氟乙烯基)哌啶-1-基)-1-环丙基-6-氟-8-甲氧基-4-氧代-1,4-二氢喹啉-3-羧酸的前药、含有它们的制药组合物以及所述前药和制药组合物作为抗微生物药物，特别是对抗耐药微生物的用途。
• DPP4 INHIBITOR AND PHARMACEUTICAL USE THEREOF
  申请人：Ijichi Chiori

  公开号：US20080175837A1

  公开（公告）日：2008-07-24

  The present invention provides a Dpp4 inhibitor which comprises a leucine derivative of the following formula (1) or a methionine derivative of the following formula (2): wherein each R1 and R3 represents a hydrogen atom (H) and an L-amino acid residue; R2 represents a hydroxyl group (OH), alkoxy group having 1 to 6 carbon atoms, amino group (NH2), alkylamino group having 1 to 6 carbon atoms, glycine residue, β-alanine residue, L-amino acid (except for proline, alanine and phenylalanine) residue or L-amino-acid amide (except for proline amide, alanine amide and phenylalanine amide) residue; and R4 represents a hydroxyl group (OH), alkoxy group having 1 to 6 carbon atoms, amino group (NH2), alkylamino group having 1 to 6 carbon atoms, glycine residue, β-alanine residue, L-amino acid (except for proline and alanine) residue or L-amino-acid amide (except for proline amide and alanine amide) residue. These derivatives also act as autophagy regulators.

  本发明提供了一种Dpp4抑制剂，其包括以下式(1)的亮氨酸衍生物或以下式(2)的甲硫氨酸衍生物：其中每个R1和R3代表氢原子（H）和L-氨基酸残基；R2代表羟基（OH），具有1到6个碳原子的烷氧基，氨基（NH2），具有1到6个碳原子的烷基氨基，甘氨酸残基，β-丙氨酸残基，L-氨基酸（除脯氨酸、丙氨酸和苯丙氨酸外）残基或L-氨基酸酰胺（除脯氨酸酰胺、丙氨酸酰胺和苯丙氨酸酰胺外）残基；以及R4代表羟基（OH），具有1到6个碳原子的烷氧基，氨基（NH2），具有1到6个碳原子的烷基氨基，甘氨酸残基，β-丙氨酸残基，L-氨基酸（除脯氨酸和丙氨酸外）残基或L-氨基酸酰胺（除脯氨酸酰胺和丙氨酸酰胺外）残基。这些衍生物还作为自噬调节剂。
• Theranostics platform and methods of use
  申请人：Sanford Burnham Prebys Medical Discovery Institute

  公开号：US10161929B2

  公开（公告）日：2018-12-25

  Theranostics platforms for identifying drugs and nutraceuticals for treatment of rare disease are described. The platforms comprise (a) a cell-phenotype image-enhancing instrument; (b) a drug/nutraceutical library; and (c) a computer-implemented system for analyzing a response of an optically-visible rare-disease cell phenotype to a drug or nutraceutical from the drug/nutraceutical library.

  本文描述了用于识别治疗罕见病的药物和营养保健品的血清学平台。这些平台包括：(a) 细胞表型图像增强仪器；(b) 药物/营养保健品库；(c) 计算机实施系统，用于分析光学可视罕见疾病细胞表型对药物/营养保健品库中药物或营养保健品的反应。
• PRO-DRUGS OF (E) -7- (3- (2-AMINO-1-FLUOROETHYLIDENE) PIPERIDIN-1-YL) -1-CYCLOPROPYL-6-FLUORO-8-METHOXY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID
  申请人：Janssen Pharmaceutica, N.V.

  公开号：EP2523948A1

  公开（公告）日：2012-11-21
• US5543397A
  申请人：——

  公开号：US5543397A

  公开（公告）日：1996-08-06